Johnson & Johnson gets atrial fibrillation technology in $63 million deal
This article was originally published in Clinica
Executive Summary
Johnson & Johnson has bought Atrionix, which is developing a catheter-based system for the treatment of atrial fibrillation (AF), for $62.8 million in cash.